- Global Pharma News & Resources

Santhera Completes Capital Increase for Financing Arrangements

Pratteln, Switzerland, September 23, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces completion of the ordinary capital increase resolved by its shareholders on June 22, 2021. Santhera's share capital currently amounts to CHF 46,470,235.


On September 22, 2021, 9,972,502 shares were issued in an ordinary capital increase to investors who subscribed for Santhera shares in the private placement announced on September 20, 2021. The new shares will be listed as per September 23, 2021. In addition, Santhera updated its articles of association to reflect past share issuances out of the conditional capital for employee participation and out of the conditional capital for financings.


Santhera plans to issue the remaining shares subscribed by investors in the private placement on or around September 24, 2021.


About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit

Editor Details

Related Links

Last Updated: 23-Sep-2021